Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

A panel of leading experts representing different sectors of the health care community met to discuss the significant and underestimated burden psoriasis and psoriatic arthritis have on patients, the health care system and economy, and the impact medical innovation has on reducing these burdens. [More]
Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment. [More]
ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

ZO Skin Health, Inc. and Cellogique Corporation are pleased to announce the launch of the ZO Medical product line to the Middle East region at The Dubai World Dermatology & Laser Conference & Exhibition – Dubai Derma, April 8-10, 2014. [More]
New high-risk cancer causing mutation identified for melanoma development

New high-risk cancer causing mutation identified for melanoma development

Researchers have discovered that mutations in a specific gene are responsible for a hereditary form of melanoma. [More]

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). [More]

Rosa/KressWorks Foundation completes first milestone in development of Ewing's sarcoma PhysioPD Platform

Rosa & Co. LLC and the KressWorks Foundation are pleased to announce the completion of the Ewing's sarcoma PhysioMap®. Completion of the PhysioMap is the first milestone in the development of the Ewing's sarcoma PhysioPD Platform. [More]
EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. [More]

More skin cancer awareness needed for minorities, says Henry Ford Hospital dermatologist

More awareness about skin cancer is needed for minorities because they believe they are at low risk of developing it, says Henry Ford Hospital dermatologist Diane Jackson-Richards, M.D. [More]

‘Residual risk’ concern for treated Japanese hypertension patients

Physicians should be alert to other sources of cardiovascular risk in patients with hypertension, even if they are receiving optimal antihypertensive treatment, say Japanese researchers. [More]
Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. [More]

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy". [More]
Study shows effect of oral fungal yeast in inhibiting thrush

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida. [More]
Japanese PAH patient prognosis ‘good’

Japanese PAH patient prognosis ‘good’

Japanese patients respond well to pulmonary arterial hypertension-targeted drugs and may have a good prognosis with long-term survival, study findings suggest. [More]

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]
Clinipace Worldwide closes merger with Choice Pharma

Clinipace Worldwide closes merger with Choice Pharma

Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the closing of its merger with Choice Pharma, a Pan-Asian contract research organization. Bringing these organizations together strengthens Clinipace Worldwide's operational and therapeutic expertise in Asia, a region in high demand by Clinipace's clients. [More]

Family CV history indicates intensive treatment need for hypertensive patients

A family history of premature cardiovascular disease is a marker of increased mortality risk in patients with hypertension, report researchers. [More]
Skin cancer may increase risk of other cancers later in life

Skin cancer may increase risk of other cancers later in life

Australian author on the paper, Professor Rodney Sinclair, Professor of Medicine at the University of Melbourne and Director of Dermatology at Epworth HealthCare said that the risk decreased significantly with increasing age, but it remains higher compared with individuals who have never had NMSC. [More]

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Exposure to UV light may exacerbate melanoma cells to creep outside blood vessels

Exposure to UV light may exacerbate melanoma cells to creep outside blood vessels

Based on the pioneering work of Dr. Claire Lugassy and Dr. Raymond Barnhill at UCLA's Jonsson Comprehensive Cancer Center, a new study provides additional support for a process by which melanoma cells, a deadly form of skin cancer, can spread throughout the body by creeping like tiny spiders along the outside of blood vessels without ever entering the blood stream, and that this process is exacerbated by exposure to ultraviolet (UV) light. [More]

Doctor to unveil new treatment systems from ZO Skin Health at AAD Annual Meeting

Dermatologist Zein Obagi, MD, founder and medical director of ZO Skin Health, Inc., announces new breakthrough treatment systems from ZO Skin Health, Inc. at the American Academy of Dermatology (AAD) Annual Meeting, Booth #3749, in Denver March 21-25, 2014. [More]